Anti-Xa Stability of Diluted Enoxaparin for Use in Pediatrics

Annals of Pharmacotherapy

Volumn 38, Issue 4, 2004, Pages 569-573

  Dager, William E ^a,b,c   Gosselin, Robert C ^a   King, Jeffery H ^a,b   Christensen, Cinda L ^a,b   Owings, John T ^a   Larkin, Edward C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Enoxaparin; Low molecular weight heparin; Pediatrics; Stability

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; GLASS;

ANTICOAGULATION; ARTICLE; DILUTION; DOSE RESPONSE; DRUG STORAGE; FREEZING; PRIORITY JOURNAL; ROOM TEMPERATURE; STORAGE TEMPERATURE; SYRINGE;

ANTICOAGULANTS; ANTITHROMBIN III; DRUG STABILITY; DRUG STORAGE; ENOXAPARIN; GLASS; HUMANS; INJECTIONS, INTRAVENOUS; PEDIATRICS; PHARMACEUTICAL SOLUTIONS; PLASTICS; SYRINGES; TEMPERATURE;

EID: 1542639512     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D107     Document Type: Article

References (12)

1. Monagle P, Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest 2001;119(1 suppl):344S-70S.
2. Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996;128:313-8.
3. deVerber G, Chan A, Monagle P, Marzinotto V, Armstrong D, Massicotte P, et al. Anticoagulation therapy in pediatric patients with sinovenous thrombosis. Arch Neurol 1998;55:1533-7.
4. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
5. Andrew M, deVerber G. Pediatric thromboembolism and stroke protocols. Hamilton, Ontario: BC Decker, 1997.
6. Frantzen HG, Abildgaard U, Aasen AO. Simplified assay or antithrombin III activity using chromogenic peptide substrate. Manual and automated method. Scand J Haematol 1983;31:427-36.
7. Charland SL, Davis DD, Tillman DJ. Activity of enoxaparin sodium in tuberculin syringes for 10 days. Am J Health Syst Pharm 1998;55:1296-8.
8. Hamilton MA, Stang L, Etches WS, Rennie RP, Mant MJ. Stability of low molecular weight heparins (LMWH's) stored in plastic syringes (abstract). Blood 2000;96:652a.
9. Turner KA, Haines ST, Poli JE. Activity of tinzaparin sodium in extemporaneously prepared syringes (abstract). Presented at: American Society of Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, December 6, 2000.
10. Dix D, Andrew M, Marzinotto V, Charpentier K, Bridge S, Monagle P, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000;136:439-45.
11. Albisetti M, Andrew M. Low molecular weight heparin in children. Eur J Pediatr 2002;161:71-7.
12. Package insert. Lovenox (enoxaparin sodium injection). Bridgewater, NJ: Aventis, December 2003.